Meglei Anastasiia Yurevna, Nedorubova Irina Alekseevna, Basina Viktoriia Pavlovna, Chernomyrdina Viktoria Olegovna, Goldshtein Dmitry Vadimovich, Bukharova Tatiana Borisovna
Research Centre for Medical Genetics, 115478 Moscow, Russia.
Int J Mol Sci. 2025 Aug 30;26(17):8457. doi: 10.3390/ijms26178457.
In regenerative medicine, orthobiologics, particularly platelet-rich plasma (PRP), are widely used due to their ability to enhance natural tissue repair mechanisms. PRP contains a concentrated pool of growth factors and cytokines that enhance regeneration while also acting as a biomimetic scaffold, thereby optimizing the microenvironment for tissue healing. In bone tissue engineering, PRP is commonly combined with synthetic or natural biomaterials, as its fibrin matrix alone lacks sufficient mechanical stability. However, even such composite systems frequently exhibit limited osteoinductive capacity, necessitating further supplementation with bioactive components. This review evaluates the regenerative potential of PRP in bone defect healing when combined with osteoinductive agents in preclinical in vivo models. We present compelling experimental evidence supporting the efficacy of this combined therapeutic approach.
在再生医学中，骨生物制品，尤其是富含血小板血浆（PRP），因其能够增强自然组织修复机制而被广泛应用。PRP含有浓缩的生长因子和细胞因子池，这些因子既能促进再生，又能作为仿生支架，从而优化组织愈合的微环境。在骨组织工程中，PRP通常与合成或天然生物材料结合使用，因为其单独的纤维蛋白基质缺乏足够的机械稳定性。然而，即使是这样的复合系统也常常表现出有限的骨诱导能力，因此需要进一步补充生物活性成分。本综述评估了PRP与骨诱导剂联合应用于临床前体内模型中骨缺损愈合时的再生潜力。我们提供了令人信服的数据证据来支持这种联合治疗方法的有效性。
